Thymidylate synthase (TS), DPD and TP were evaluated as potential biomarkers in stage III colon cancer patients who received adjuvant chemotherapy in the XELOX protocol or with 5-FU/Leucovorin bolus. Here, TYMS is linked to malignant colon neoplasm.